ANDA 90900, held by PharmoBedient. Galantamine Hydrobromide.
As of Nov 21, 2026, ANDA 90900 (Galantamine Hydrobromide), held by PharmoBedient, was first approved by FDA on Jan 24, 2011, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 24, 2011 | Original application | Approved | None posted |
| Galantamine HydrobromideEQ 8MG BASE · capsule, extended release;oral | Galantamine Hydrobromide | Discontinued |
| Galantamine HydrobromideEQ 16MG BASE · capsule, extended release;oral | Galantamine Hydrobromide | Discontinued |
| Galantamine HydrobromideEQ 24MG BASE · capsule, extended release;oral | Galantamine Hydrobromide | Discontinued |
| Oct 25, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Apr 28, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 9, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 9, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 24, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters